Market Update: AbbVie Inc (NYSE:ABBV) – Myriad and AbbVie Sign Expanded Agreement for Tumor BRACAnalysis CDx(TM)

[GlobeNewswire] – SALT LAKE CITY — Myriad Genetics, Inc. announced today that it has signed an expanded companion diagnostic agreement with AbbVie, Inc. , a leading global biopharmaceutical company to use Tumor BRACAnalysis . . . → Read More: Market Update: AbbVie Inc (NYSE:ABBV) – Myriad and AbbVie Sign Expanded Agreement for Tumor BRACAnalysis CDx(TM) Similar Articles: Market Update (NYSE:ABBV): AbbVie Reports Third-Quarter 2014 Financial Results Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie Declares Quarterly Dividend Market Update (NYSE:ABBV): AbbVie, Teva broke law in AndroGel "pay for delay" deal, U.S. says